| Cat. No. |
Product Name |
Information |
| PC-28780 |
MKK3 modulator (R)-48
MKK3 modulator
|
MKK3 modulator (R)-48 is a highly potent, selective, orally bioavailable, non-ATP-competitive MKK3 allosteric modulator with SPR KD of 3.35 nM, exhibits potent TNF-α inhibitory activity with IC50 of 38 nM in RAW264.7 cells. |
| PC-28485 |
ASC69
MAP2K7 inhibitor
|
ASC69 (ASC-69, APY69) is a small-molecule ligand as a PD/PD-L1 inhibitor, also potently inhibits MAP2K7 (MEK7, MKK7) with IC50 of 0.8 nM, inhibits T-ALL and elicits strong anti-leukemic effects by inducing cell-cycle arrest and apoptosis. |
| PC-28335 |
Gossypetin
MKK3/MKK6 inhibitor
|
Gossypetin is a hexahydroxylated flavonoid within antioxidant, antibacterial and anticancer activities, is a potent inhibitor of MKK3 and MKK6, also is a USP5-Cav3.2 disruptor. |
| PC-27483 |
Nuvrumetinib
MEK1/2 inhibitor
|
Nuvrumetinib (PAS-004) is a potent, selective, next-generation macrocyclic MEK1/2 inhibitor. |
| PC-24957 |
FCN-159
MEK1/2 inhibitor
|
FCN-159 (Luvometinib) is an orally available and highly potent selective MEK1/2 inhibitor. |
| PC-24109 |
Atebimetinib
MEK inhibitor
|
Atebimetinib (IMM-1-104) is a potent, selective and allosteric MEK tyrosine kinase inhibitor with antineoplastic activity, potently inhibits ERK phosphorylation in vitro and in vivo. |
| PC-22721 |
Vacquinol-1 dihydrochloride
MKK4 activator
|
Vacquinol-1 (NSC 13316) dihydrochloride is a specific MKK4 (MAP2K4, MEK4) activator that induces vacuolization, induces ATP depletion in glioblastoma cells (IC50 = 3.14 uM) without affecting fibroblasts, embryonic stem cells, or osteosarcoma cells. |
| PC-21799 |
HRX-0233
MAP2K4 inhibitor
|
HRX-0233 (HRX0233) is a potent, selective MAP2K4 (MKK4) inhibitor, HRX-0233 is synergistic with RAS inhibitors in KRAS-mutant cancers. |
| PC-21237 |
NFX-179
MEK inhibitor
|
NFX-179 (Nedometinib, NFX179) is a potent, specific, topical, metabolically labile MEK1/2 inhibitor with biochemical IC50 of 135 nM (MEK1). |
| PC-20654 |
DK2403
MAP2K7 inhibitor
|
DK2403 (DK-2403) is a highly potent, selective and covalent MAP2K7 (MEK7) inhibitor with IC50 of 10 nM, covalently engages the unique Cys218 residue within the active site. |
| PC-20026 |
HRX215
MKK4 inhibitor
|
Darizmetinib (HRX215, HRX0215) is a first-in-class, potent, selective inhibitor of MKK4 (mitogen-activated protein kinase kinase 4, MEK4, MAP2K4) with IC50 of 20 nM, >100-fold selectivity against JNK1, BRAF, and MKK7. |
| PC-49771 |
Binimetinib
MEK inhibitor
|
Binimetinib (ARRY-162, ARRY-438162, MEK162) is a potent, selective and non-competitive inhibitor of MEK1/2 with IC50 of 12 nM in cell-free assays. |
